Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 5, 2005
Last updated: August 18, 2012
Last verified: July 2007

RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving docetaxel and carboplatin together with pegfilgrastim before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well giving docetaxel and carboplatin together with pegfilgrastim works in treating patients who are undergoing surgery for stage II or stage III breast cancer.

Condition Intervention Phase
Breast Cancer
Biological: pegfilgrastim
Drug: carboplatin
Drug: docetaxel
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Pathological complete response rate by histologic evaluation at definitive surgery [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity profile by CTCAE v3.0 at baseline and each subsequent evaluation [ Designated as safety issue: Yes ]
  • Rate of breast conserving surgery at definitive surgery after neoadjuvant chemotherapy [ Designated as safety issue: No ]
  • Clinical response rate by clinical examination prior to definitive surgery [ Designated as safety issue: No ]

Estimated Enrollment: 58
Study Start Date: August 2005
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the pathological complete response rate in patients with stage II or III breast cancer treated with neoadjuvant docetaxel, carboplatin, and pegfilgrastim.


  • Determine the toxicity profile of this regimen in these patients.
  • Determine the rate of breast-conserving surgery in patients treated with this regimen.
  • Determine the clinical response rate in patients treated with this regimen.
  • Determine the feasibility of drug administration, in terms of the percent of planned dose actually administered per course, in patients treated with this regimen.
  • Determine the proportion of patients with negative pathologic lymph node status after treatment with this regimen.
  • Determine the proportion of patients with residual ductal carcinoma in situ after treatment with this regimen.

OUTLINE: This is a multicenter study.

Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.

After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years.

PROJECTED ACCRUAL: A total of 25-58 patients will be accrued for this study within 21-23 months.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of breast cancer

    • Clinical stage II or III disease (including T2-4, N0-3)
  • No clinical or radiological evidence of distant metastases

    • Isolated supraclavicular lymph node involvement allowed
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Male or female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-1

Life expectancy

  • At least 3 months


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10.0 g/dL


  • Bilirubin normal
  • Meets 1 of the following criteria:

    • AST or ALT ≤ 5 times upper limit of normal (ULN) AND alkaline phosphatase normal
    • AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN
    • AST or ALT normal AND alkaline phosphatase ≤ 5 times ULN


  • Creatinine clearance ≥ 30 mL/min


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 30 days after study treatment
  • No active unresolved infection
  • No history of severe hypersensitivity reaction to docetaxel, carboplatin, or any other drug formulated with polysorbate 80
  • No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or pegfilgrastim
  • No peripheral neuropathy ≥ grade 2
  • No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • No prior surgical resection for invasive breast cancer


  • No other prior therapy for invasive breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00107510

  Show 120 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Study Chair: Vivek Roy, MD, FACP Mayo Clinic
Investigator: Edith A. Perez, MD Mayo Clinic
Investigator: Robert T. Chambers, MD, FRCSC, FACS MeritCare Wahpeton
Investigator: Judith E. Hurley, MD University of Miami Sylvester Comprehensive Cancer Center
  More Information

Additional Information:
Apsey H, Roy V, Pockaj B, et al.: Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer". [Abstract] J Clin Oncol 27 (Suppl 15): A-623, 2009.
Pockaj BA, Mukherjee P, Tinder TL, et al.: NCCTG N0338: effect of docetaxel and carboplatin on VEGF, PGE2, and immune cells in patients with stage II or III breast cancer. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, Texas. A-5110, 2008.
Reinholz MM, Kitzmann KK, Hillman D, et al.: Differential gene expression in circulating tumor cells between primary and metastatic breast cancer patients. [Abstract] Breast Cancer Res Treat 106 (1): A-5022, S213-4, 2007. Identifier: NCT00107510     History of Changes
Other Study ID Numbers: CDR0000420834, NCCTG-N0338
Study First Received: April 5, 2005
Last Updated: August 18, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
male breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on July 01, 2015